MDS Latest News

Patient support group welcomes NICE decision to re-appraise Vidaza

London, 26 July 2010 – The MDS UK Patient Support Group has welcomed the decision announced today by the National Institute for Health and Clinical Excellence (NICE) that it will re-appraise the use of Vidaza (azacitidine)in patients with higher-risk myelodysplastic syndrome (MDS)- a group of debilitating bone marrow diseases.

Read full story

Cancer patient support groups to appeal negative NICE decision

The MDS UK Patient Support Group has announced that it has lodged an appeal against the negative recommendation issued earlier this month by the National Institute for Health and Clinical Excellence (NICE) for the use of Vidaza (azacitidine) in patients with higher-risk myelodysplastic syndrome (MDS).

Read full story